Skip to main content

Table 3 Association between csDMARDs and clinical response (∆BASDAI ≥ 2.0) or remission (BASDAI < 2 and CRP ≤ 5 mg/L) at 1 year, stratified for body mass index

From: Association between concomitant csDMARDs and clinical response to TNF inhibitors in overweight patients with axial spondyloarthritis

 

BMI ≤ 25 (n = 60; 42%)

BMI > 25 (n = 81; 58%)

OR

95% CI

OR

95% CI

Clinical response

 Any csDMARD

1.10

0.33–3.58

7.86

2.39–25.78*

 MTX [± SSZ]

1.04

0.25–4.25

9.82

2.13–45.20*

 SSZ

1.18

0.25–5.63

6.86

1.85–25.40*

Remission

 Any csDMARD

0.76

0.20–2.86

4.84

1.09–21.36*

 MTX [± SSZ]

0.60

0.11–3.18

5.56

0.84–36.52

 SSZ

0.99

0.17–5.64

4.35

0.77–24.54

  1. The adjusted multivariable logistic regression analysis included 141 patients. Two different models are presented for the following outcomes: clinical response and remission. Odds ratio (OR) and 95% confidence interval (CI) were calculated. All models were adjusted for age, gender, disease duration, HLA-B27, baseline BASDAI and CRP. *p value < 0.05 was considered statistically significant. BMI body mass index, HLA-B27 human leucocyte antigen B27, CRP C-reactive protein, BASDAI Bath Ankylosing Spondylitis Disease Activity Index, csDMARD conventional synthetic disease-modifying anti-rheumatic drug, MTX methotrexate, SSZ sulfasalazine
Back to article page

Arthritis Research & Therapy

ISSN: 1478-6362

Contact us